MTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation

Journal of Hepatology

Volumn 54, Issue 2, 2011, Pages 396-398

  Waidmann, Oliver ^a   Hofmann, Wolf Peter ^a   Zeuzem, Stefan ^a   Trojan, Joerg ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Barcelona Clinic Liver Cancer; BCLC; HCC; hepatocellular carcinoma; mammalian target of rapamycin; mTOR

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SORAFENIB;

CANCER PATIENT; CANCER STAGING; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FATALITY; FATIGUE; HAND FOOT AND MOUTH DISEASE; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; SKIN TOXICITY; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 78751575990     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.08.038     Document Type: Letter

References (10)

1. S. Bhoori, S. Toffanin, C. Sposito, A. Germini, A. Pellegrinelli, and A. Lampis Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle J Hepatol 52 2010 771 775
2. A. Valdivieso, J. Bustamante, M. Gastaca, J.G. Uriarte, A. Ventoso, and P. Ruiz Management of hepatocellular carcinoma recurrence after liver transplantation Transplant Proc 42 2010 660 662
3. I. Graziadei, A. Finkenstedt, K. Nachbaur, H. Zoller, W. Mark, and W. Vogel Outcome of patients with recurrent hepatocellular carcinoma after liver transplantation J Hepatol 52 2010 A214
4. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
5. A. Villanueva, D.Y. Chiang, P. Newell, J. Peix, S. Thung, and C. Alsinet Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
6. C. Toso, S. Merani, D.L. Bigam, A.M. Shapiro, and N.M. Kneteman Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma Hepatology 51 2010 1237 1243
7. A.A. Schnitzbauer, C. Zuelke, C. Graeb, J. Rochon, I. Bilbao, and P. Burra A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma BMC Cancer 10 2010 190
8. P. Newell, S. Toffanin, A. Villanueva, D.Y. Chiang, B. Minguez, and L. Cabellos Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo J Hepatol 51 2009 725 733
9. M.W. Welker, N. Lubomierski, C. Gog, E. Herrmann, K. Engels, and T.J. Vogl Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions J Chemother 22 2010 205 211
10. B. Blanchet, B. Billemont, S. Barete, H. Garrigue, L. Cabanes, and R. Coriat Toxicity of sorafenib: clinical and molecular aspects Expert Opin Drug Saf 9 2010 275 287